In order to supply its protein COVID-19 vaccine, which will be available if authorised by the European Medicines Agency, the European Commission announced on Tuesday that it has inked a joint procurement deal with Spanish pharmaceutical company HIPRA (EMA).
In a statement, the executive of the European Union announced that 14 nations are a part of the arrangement, which allows them to purchase up to 250 million doses. The EMA is currently reviewing HIPRA’s vaccine, which the Spanish company expects will be licenced and available for use by the fall, according to a statement it released. HIPRA called the EU’s announcement a “sign of confidence” in its injection.
She added that an increase in vaccination and boosting would be crucial over the coming months, saying that the HIPRA vaccine “adds yet another option to complement our extensive vaccine portfolio for our member states and citizens.”
The HIPRA bivalent recombinant protein vaccine is being created as a booster dose for those 16 years of age and older who have already received an immunisation. It uses recombinant protein similar to those produced by American pharmaceutical company Novavax.
An executive from HIPRA told Reuters in December that the company was convinced that the experimental COVID-19 vaccine would be in high demand in the EU because it is made to guard against new variations, is portable in cold temperatures, and can be produced in large quantities.